Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Bicara and DualityBio will soon test market appetite for new oncology issues.
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.